PE20151408A1 - Anticuerpos cd47 que no agotan plaquetas ni globulos rojos y metodos de uso de los mismos - Google Patents

Anticuerpos cd47 que no agotan plaquetas ni globulos rojos y metodos de uso de los mismos

Info

Publication number
PE20151408A1
PE20151408A1 PE2015001628A PE2015001628A PE20151408A1 PE 20151408 A1 PE20151408 A1 PE 20151408A1 PE 2015001628 A PE2015001628 A PE 2015001628A PE 2015001628 A PE2015001628 A PE 2015001628A PE 20151408 A1 PE20151408 A1 PE 20151408A1
Authority
PE
Peru
Prior art keywords
antibodies
methods
platelets
exhaust
red balloons
Prior art date
Application number
PE2015001628A
Other languages
English (en)
Spanish (es)
Inventor
Brendan Eckelman
John Timmer
Amir Razai
Quinn Deveraux
Kyle Jones
Mark Lappe
Original Assignee
Inhibrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/024995 external-priority patent/WO2013119714A1/en
Application filed by Inhibrx Llc filed Critical Inhibrx Llc
Publication of PE20151408A1 publication Critical patent/PE20151408A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PE2015001628A 2013-02-06 2013-08-06 Anticuerpos cd47 que no agotan plaquetas ni globulos rojos y metodos de uso de los mismos PE20151408A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2013/024995 WO2013119714A1 (en) 2012-02-06 2013-02-06 Cd47 antibodies and methods of use thereof
US13/761,087 US9045541B2 (en) 2012-02-06 2013-02-06 CD47 antibodies and methods of use thereof
US201361815219P 2013-04-23 2013-04-23
PCT/US2013/053818 WO2014123580A1 (en) 2013-02-06 2013-08-06 Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20151408A1 true PE20151408A1 (es) 2015-10-15

Family

ID=51300031

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001628A PE20151408A1 (es) 2013-02-06 2013-08-06 Anticuerpos cd47 que no agotan plaquetas ni globulos rojos y metodos de uso de los mismos

Country Status (19)

Country Link
EP (2) EP4137518A1 (cg-RX-API-DMAC7.html)
JP (2) JP2016507555A (cg-RX-API-DMAC7.html)
KR (2) KR102170196B1 (cg-RX-API-DMAC7.html)
CN (1) CN105101997B (cg-RX-API-DMAC7.html)
AU (2) AU2013377886B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015018851A2 (cg-RX-API-DMAC7.html)
CA (1) CA2900468C (cg-RX-API-DMAC7.html)
CL (1) CL2015002203A1 (cg-RX-API-DMAC7.html)
EA (1) EA036963B1 (cg-RX-API-DMAC7.html)
ES (1) ES2944477T3 (cg-RX-API-DMAC7.html)
IL (2) IL240390B (cg-RX-API-DMAC7.html)
MX (2) MX2015010115A (cg-RX-API-DMAC7.html)
NI (1) NI201500103A (cg-RX-API-DMAC7.html)
NZ (1) NZ710695A (cg-RX-API-DMAC7.html)
PE (1) PE20151408A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501729B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201706383XA (cg-RX-API-DMAC7.html)
WO (1) WO2014123580A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201505745B (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863834C (en) 2012-02-06 2024-09-10 Inhibrx Biosciences, Inc. Anti-CD47 antibodies and their methods of use
KR20150093770A (ko) 2012-12-12 2015-08-18 베스쿨럭스 인코포레이티드 치료적 ｃｄ４７ 항체
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
LT2931752T (lt) 2012-12-17 2019-12-10 Trillium Therapeutics Inc Ligos cd47+ ląstelių gydymas su sirp alfa-fc junginiais
CN114917336A (zh) 2013-03-15 2022-08-19 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP3012271A1 (en) * 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
KR20170081699A (ko) * 2014-11-18 2017-07-12 얀센 파마슈티카 엔.브이. Cd47 항체, 방법 및 용도
KR102489471B1 (ko) * 2014-12-30 2023-01-18 셀진 코포레이션 항-cd47 항체 및 그 용도
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
AU2016225993B2 (en) * 2015-03-04 2020-09-24 Yuhan Corporation Antibody therapeutics that bind CD47
RS62151B1 (sr) 2015-08-07 2021-08-31 Alx Oncology Inc Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
JP6885606B2 (ja) * 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
AU2016326423A1 (en) 2015-09-21 2018-04-26 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
AU2017206631B2 (en) * 2016-01-11 2021-02-11 Forty Seven, LLC Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
SMT202400438T1 (it) 2016-04-14 2024-11-15 Ose Immunotherapeutics Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche
PL3442578T3 (pl) 2016-04-15 2022-06-20 The Board Of Trustees Of The Leland Stanford Junior University Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów
US11649284B2 (en) 2016-04-18 2023-05-16 Baylor College Of Medicine Cancer gene therapy targeting CD47
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
AU2017292752B2 (en) 2016-07-06 2023-07-27 Celgene Corporation Antibodies with low immunogenicity and uses thereof
US10148939B2 (en) 2016-07-19 2018-12-04 Gopro, Inc. Mapping of spherical image data into rectangular faces for transport and decoding across networks
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODY
CN108779179B (zh) * 2016-11-28 2022-02-08 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
CN110461872B (zh) * 2017-01-26 2023-09-26 再鼎医药(上海)有限公司 Cd47抗原结合单元及其用途
JP7170331B2 (ja) * 2017-03-22 2022-11-14 アーチ オンコロジー，インコーポレイテッド 固形及び血液癌の治療のための併用療法
EP3601351A1 (en) * 2017-03-27 2020-02-05 Celgene Corporation Methods and compositions for reduction of immunogenicity
ES2976558T3 (es) 2017-06-21 2024-08-05 The Board Of Trustees Of The Leland Stanfordjunior Univ Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas
US11401329B2 (en) * 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
US11771764B2 (en) 2017-11-06 2023-10-03 Pfizer Inc. CD47 blockade with radiation therapy
WO2019091473A1 (en) * 2017-11-10 2019-05-16 I-Mab Biopharma Co., Ltd. Fusion proteins containing cd47 antibodies and cytokines
EP3712170A4 (en) * 2017-11-10 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
ES2927305T3 (es) 2018-02-12 2022-11-04 Forty Seven Inc Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
AR115418A1 (es) 2018-05-25 2021-01-13 Alector Llc ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
CA3110620C (en) * 2018-08-31 2023-06-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-cd47 antibody and application thereof
AU2019336345A1 (en) 2018-09-04 2021-04-15 Pfizer Inc. CD47 blockade with parp inhibition for disease treatment
US20210269522A1 (en) * 2018-10-31 2021-09-02 I-Mab Biopharma Us Limited Novel CD47 Antibodies and Methods of Using Same
TW202045550A (zh) * 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN113461817B (zh) * 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
AR121805A1 (es) * 2020-04-10 2022-07-13 Hutchison Medipharma Ltd Anticuerpo anti-cd47 y usos del mismo
US20230159663A1 (en) * 2020-04-24 2023-05-25 Virtuoso Binco, Inc. Bispecific antibodies for treating cd47-associated diseases
US20230303711A1 (en) * 2020-07-31 2023-09-28 Bio-Thera Solutions, Ltd. Anti-cd47 antibody and use thereof
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CA3206138A1 (en) * 2020-12-23 2022-06-30 Yongting HUO Antibody targeting cd47 and application thereof
JP7699210B2 (ja) * 2021-01-08 2025-06-26 北京韓美薬品有限公司 Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント
MX2023010916A (es) 2021-03-17 2023-12-14 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas.
JP2024515211A (ja) 2021-04-27 2024-04-05 ファイザー・インク Ｄｈｆｒ阻害剤を用いたｃｄ４７遮断療法の増強
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
WO2023073580A1 (en) 2021-10-29 2023-05-04 Pfizer Inc. Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
CN118221812A (zh) * 2022-12-14 2024-06-21 上海迈石生物技术有限公司 一种靶向cd47的单克隆抗体及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5057604A (en) 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
DE69331089T2 (de) 1992-02-18 2002-07-18 Otsuka Kagaku K.K., Osaka Beta-Laktam und Cepham Verbindungen und Ihre Herstellung
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
AU1925195A (en) 1994-02-22 1995-09-04 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE352613T1 (de) 1995-08-29 2007-02-15 Kirin Brewery Chimäres tier und methode zu dessen herstellung
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ES2230848T3 (es) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
TWI242043B (en) * 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
US7282556B2 (en) * 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
JP4637749B2 (ja) * 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
AR069495A1 (es) * 2007-11-30 2010-01-27 Glaxo Group Ltd Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
US8420784B2 (en) * 2008-05-27 2013-04-16 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor, (IL-10R) antibodies
WO2010017598A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Anti-il-12/il-23 antibodies
EP3181149A1 (en) * 2010-05-14 2017-06-21 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CA2863834C (en) * 2012-02-06 2024-09-10 Inhibrx Biosciences, Inc. Anti-CD47 antibodies and their methods of use
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
PH12015501729A1 (en) 2015-10-19
NI201500103A (es) 2016-09-29
NZ710695A (en) 2020-05-29
KR102170196B1 (ko) 2020-10-26
EA036963B1 (ru) 2021-01-20
AU2019200942B2 (en) 2021-01-21
JP6726238B2 (ja) 2020-07-22
PH12015501729B1 (en) 2015-10-19
CA2900468C (en) 2024-04-30
IL240390A0 (en) 2015-09-24
WO2014123580A8 (en) 2015-10-22
MX2021008851A (es) 2021-09-08
SG10201706383XA (en) 2017-09-28
CN105101997B (zh) 2018-11-09
EP2953643B1 (en) 2023-02-22
JP2018177813A (ja) 2018-11-15
SG11201506132PA (en) 2015-09-29
ZA201905292B (en) 2022-09-28
IL274566B (en) 2021-10-31
EP2953643A1 (en) 2015-12-16
IL274566A (en) 2020-06-30
EP2953643A4 (en) 2016-11-09
CL2015002203A1 (es) 2016-01-29
KR20150123825A (ko) 2015-11-04
ES2944477T3 (es) 2023-06-21
CN105101997A (zh) 2015-11-25
AU2019200942A1 (en) 2019-02-28
IL240390B (en) 2020-05-31
AU2013377886B2 (en) 2018-11-29
ZA201505745B (en) 2020-02-26
HK1218863A1 (en) 2017-03-17
KR20200123270A (ko) 2020-10-28
JP2016507555A (ja) 2016-03-10
EA201500818A1 (ru) 2016-02-29
CA2900468A1 (en) 2014-08-14
AU2013377886A1 (en) 2015-09-03
WO2014123580A1 (en) 2014-08-14
BR112015018851A2 (pt) 2017-07-18
MX2015010115A (es) 2016-05-31
EP4137518A1 (en) 2023-02-22
KR102276974B1 (ko) 2021-07-13

Similar Documents

Publication Publication Date Title
PE20151408A1 (es) Anticuerpos cd47 que no agotan plaquetas ni globulos rojos y metodos de uso de los mismos
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
CO2019001980A2 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
AR112048A1 (es) Anticuerpos cd47 y métodos de uso de los mismos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
MX2021003549A (es) Anticuerpos dobles especificos.
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
MX2013013832A (es) Proteínas de unión receptoras fc.
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2

Legal Events

Date Code Title Description
FG Grant, registration